ROIV
$35.72+0.62%
as of close, Oct 2, 2026
☾ AH $35.72 +0.62%
Roivant Sciences Ltd.Stock · Health CareNasdaq Composite 0.05%Russell 1000 0.02%US Stock Market 0.02%Russell 3000 0.02%
ROIV SEC filings (2026)
CIK 1635088 · Pharmaceutical Preparations (SIC 2834) · incorporated in D0 · fiscal year ends in March
980 filings on EDGAR since 2015 · 5 annual, 16 quarterly, 81 current · financial statements · earnings
Latest 10-K
May 20, 2026
fiscal year to Mar 31, 2026
Latest 10-Q
Aug 6, 2026
quarter to Jun 30, 2026
Latest 8-K
Sep 18, 2026
Shareholder vote results
Last earnings release
Aug 6, 2026
−$0.45 vs −$0.45 · ▲ 1.5%
Filings on file
980
since 2015, 679 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by what they covered, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
September 2026
- Sep 30Insider saleVenker Eric (President & Immunovant CEO) sold 200,000 shares for $7.3M at $36.62 under a 10b5-1 plan
- Sep 188-K8-K · Shareholder vote results
- Sep 15Insider saleFitzgerald Meghan (Director) sold 5,112 shares for $203K at $39.68–$40.45 under a 10b5-1 plan
- Sep 15Insider saleEpperly Melissa B, (Director) sold 4,938 shares for $196K at $39.65–$40.38 under a 10b5-1 plan
- Sep 8Insider saleFitzgerald Meghan (Director) sold 20,000 shares for $798K at $39.90 under a 10b5-1 plan
- Sep 88-K8-K · Regulation FD disclosure
August 2026
- Aug 28Insider saleVenker Eric (President & Immunovant CEO) sold 200,000 shares for $7.2M at $35.63–$36.44 under a 10b5-1 plan
- Aug 288-K8-K · Other events
- Aug 278-K8-K · Regulation FD disclosure
- Aug 21Insider saleSukhatme Mayukh (President & CIO · Director) sold 144,756 shares for $5.3M at $36.48
- Aug 20Insider saleSukhatme Mayukh (President & CIO · Director) sold 17,519 shares for $653K at $37.30
- Aug 19Insider saleSukhatme Mayukh (President & CIO · Director) sold 172,899 shares for $6.4M at $37.17
- Aug 18Insider saleSukhatme Mayukh (President & CIO · Director) sold 136,942 shares for $5.0M at $36.59–$37.18
- Aug 17Insider saleSukhatme Mayukh (President & CIO · Director) sold 284,707 shares for $10.3M at $36.25
- Aug 14Insider saleSukhatme Mayukh (President & CIO · Director) sold 243,177 shares for $8.8M at $36.23
- Aug 6EarningsEarnings release — EPS −$0.45 vs −$0.45 est. (+0.0%); revenue $1.4M (−34% y/y) 1.5%
- Aug 6ReportQuarterly report, Q1 2026 — revenue $1.4M (−34% y/y), net income −$189.8M, EPS −$0.26
July 2026
- Jul 29ProxyProxy · Annual report to shareholders
- Jul 29ProxyProxy · Additional proxy materials
- Jul 29ProxyProxy · Proxy statement
- Jul 27Insider saleVenker Eric (President & Immunovant CEO) sold 200,000 shares for $7.0M at $34.95 under a 10b5-1 plan
June 2026
- Jun 30Insider saleMANCHESTER KEITH S (Director) sold 212,380 shares for $7.5M at $35.28–$35.45
- Jun 30Insider saleQVT Financial LP (Director by Deputization) sold 12,380 shares for $437K at $35.28
- Jun 30Insider saleGold Daniel Allen (Director) sold 12,380 shares for $437K at $35.28
- Jun 30Insider saleFitzgerald Meghan (Director) sold 10,000 shares for $349K at $34.90 under a 10b5-1 plan
- Jun 29Insider saleQVT Financial LP (Director by Deputization) sold 800,000 shares for $27.6M at $34.44–$34.59
- Jun 29Insider saleGold Daniel Allen (Director) sold 800,000 shares for $27.6M at $34.44–$34.59
- Jun 29Insider saleMANCHESTER KEITH S (Director) sold 800,000 shares for $27.6M at $34.44–$34.59
- Jun 29Insider saleEpperly Melissa B, (Director) sold 17,750 shares for $610K at $34.32–$34.71 under a 10b5-1 plan
- Jun 26Insider saleQVT Financial LP (Director by Deputization) sold 625,783 shares for $21.3M at $33.92–$34.07
- Jun 26Insider saleGold Daniel Allen (Director) sold 625,783 shares for $21.3M at $33.92–$34.07
- Jun 26Insider saleMANCHESTER KEITH S (Director) sold 625,783 shares for $21.3M at $33.92–$34.07
- Jun 26Insider saleSukhatme Mayukh (President & CIO · Director) sold 500,000 shares for $17.0M at $34.08
- Jun 25Insider saleSukhatme Mayukh (President & CIO · Director) sold 500,000 shares for $17.1M at $34.13
- Jun 24Insider saleVenker Eric (President & Immunovant CEO) sold 200,000 shares for $6.6M at $33.05–$33.51 under a 10b5-1 plan
May 2026
- May 22Insider saleVenker Eric (President & Immunovant CEO) sold 200,000 shares for $6.1M at $30.27 under a 10b5-1 plan
- May 20EarningsEarnings release — EPS −$0.46 vs −$0.38 est. (−21.1%); revenue $2.5M (−67% y/y) 14.9%
- May 20ReportAnnual report, FY2025 — revenue $8.3M (−72% y/y), net income −$299.8M, EPS −$0.54
April 2026
- Apr 20Insider saleVenker Eric (President & Immunovant CEO) sold 200,000 shares for $5.9M at $29.59 under a 10b5-1 plan
- Apr 16Insider saleGline Matthew (CEO · Director) sold 289,774 shares for $8.4M at $29.16
- Apr 8Insider saleHumes Jennifer (Chief Accounting Officer) sold 13,538 shares for $384K at $28.37
- Apr 28-K8-K · Results of operations; Regulation FD disclosure
March 2026
- Mar 26Insider saleFitzgerald Meghan (Director) sold 70,000 shares for $1.9M at $27.45
- Mar 238-K8-K · Material definitive agreement
- Mar 17Insider saleVenker Eric (President & Immunovant CEO) sold 200,000 shares for $5.6M at $28.24 under a 10b5-1 plan
- Mar 16Insider saleEpperly Melissa B, (Director) sold 41,861 shares for $1.2M at $28.68
- Mar 38-K8-K · Material definitive agreement; Regulation FD disclosure; Other events
- Mar 38-K8-K · Regulation FD disclosure
February 2026
- Feb 23Insider saleTorti Frank (President and Vant Chair) sold 587,390 shares for $16.2M at $27.51 under a 10b5-1 plan
- Feb 20Insider saleTorti Frank (President and Vant Chair) sold 1,012,610 shares for $27.5M at $27.15 under a 10b5-1 plan
- Feb 19Insider saleTorti Frank (President and Vant Chair) sold 1,400,000 shares for $38.4M at $27.42 under a 10b5-1 plan
- Feb 13Insider saleQVT Financial LP (Director by Deputization) sold 375,784 shares for $10.0M at $26.49–$26.50
- Feb 13Insider saleGold Daniel Allen (Director) sold 375,784 shares for $10.0M at $26.49–$26.50
- Feb 13Insider saleMANCHESTER KEITH S (Director) sold 375,784 shares for $10.0M at $26.49–$26.50
- Feb 13Insider saleVenker Eric (President & Immunovant CEO) sold 200,000 shares for $5.3M at $26.49 under a 10b5-1 plan
- Feb 12Insider saleQVT Financial LP (Director by Deputization) sold 425,000 shares for $11.4M at $26.72–$26.76
- Feb 12Insider saleGold Daniel Allen (Director) sold 425,000 shares for $11.4M at $26.72–$26.76
- Feb 12Insider saleMANCHESTER KEITH S (Director) sold 425,000 shares for $11.4M at $26.72–$26.76
- Feb 11Insider saleQVT Financial LP (Director by Deputization) sold 425,000 shares for $11.3M at $26.67
- Feb 11Insider saleGold Daniel Allen (Director) sold 425,000 shares for $11.3M at $26.67
- Feb 11Insider saleMANCHESTER KEITH S (Director) sold 425,000 shares for $11.3M at $26.67
- Feb 9Insider saleSukhatme Mayukh (President & CIO · Director) sold 339,441 shares for $9.0M at $26.47
- Feb 6EarningsEarnings release — EPS −$0.36 vs −$0.39 est. (+7.7%); revenue $2.0M (−78% y/y) 22.1%
- Feb 6ReportQuarterly report, Q3 2025 — revenue $2.0M (−78% y/y), net income −$265.9M, EPS −$0.38
January 2026
December 2025
- Dec 118-K8-K · Regulation FD disclosure
November 2025
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $484.3M in 48 sales and bought nothing on the open market; 113 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Sep 30, 2026Form 4 | Venker EricPresident & Immunovant CEOSold · $7.3M · 200,000 sh · 10b5-1 |
| Sep 15, 2026Form 4 | Fitzgerald MeghanDirectorSold · $203K · 5,112 sh · 10b5-1 |
| Sep 15, 2026Form 4 | Epperly Melissa B,DirectorSold · $196K · 4,938 sh · 10b5-1 |
| Sep 8, 2026Form 4 | Fitzgerald MeghanDirectorSold · $798K · 20,000 sh · 10b5-1 |
| Aug 28, 2026Form 4 | Venker EricPresident & Immunovant CEOSold · $7.2M · 200,000 sh · 10b5-1 |
| Aug 21, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorSold · $5.3M · 144,756 sh |
| Aug 20, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorSold · $653K · 17,519 sh |
| Aug 19, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorSold · $6.4M · 172,899 sh |
| Aug 18, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorSold · $5.0M · 136,942 sh |
| Aug 17, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorSold · $10.3M · 284,707 sh |
| Aug 14, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorSold · $8.8M · 243,177 sh |
| Jul 27, 2026Form 4 | Venker EricPresident & Immunovant CEOSold · $7.0M · 200,000 sh · 10b5-1 |
| Jun 30, 2026Form 4 | MANCHESTER KEITH SDirectorSold · $7.5M · 212,380 sh |
| Jun 30, 2026Form 4 | QVT Financial LPDirector by DeputizationSold · $437K · 12,380 sh |
| Jun 30, 2026Form 4 | Gold Daniel AllenDirectorSold · $437K · 12,380 sh |
| Jun 30, 2026Form 4 | Fitzgerald MeghanDirectorSold · $349K · 10,000 sh · 10b5-1 |
| Jun 29, 2026Form 4 | QVT Financial LPDirector by DeputizationSold · $27.6M · 800,000 sh |
| Jun 29, 2026Form 4 | Gold Daniel AllenDirectorSold · $27.6M · 800,000 sh |
| Jun 29, 2026Form 4 | MANCHESTER KEITH SDirectorSold · $27.6M · 800,000 sh |
| Jun 29, 2026Form 4 | Epperly Melissa B,DirectorSold · $610K · 17,750 sh · 10b5-1 |
| Jun 26, 2026Form 4 | QVT Financial LPDirector by DeputizationSold · $21.3M · 625,783 sh |
| Jun 26, 2026Form 4 | Gold Daniel AllenDirectorSold · $21.3M · 625,783 sh |
| Jun 26, 2026Form 4 | MANCHESTER KEITH SDirectorSold · $21.3M · 625,783 sh |
| Jun 26, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorSold · $17.0M · 500,000 sh |
| Jun 25, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorSold · $17.1M · 500,000 sh |
| Jun 24, 2026Form 4 | Venker EricPresident & Immunovant CEOSold · $6.6M · 200,000 sh · 10b5-1 |
| May 22, 2026Form 4 | Venker EricPresident & Immunovant CEOSold · $6.1M · 200,000 sh · 10b5-1 |
| Apr 20, 2026Form 4 | Venker EricPresident & Immunovant CEOSold · $5.9M · 200,000 sh · 10b5-1 |
| Apr 16, 2026Form 4 | Gline MatthewCEO · DirectorSold · $8.4M · 289,774 sh |
| Apr 8, 2026Form 4 | Humes JenniferChief Accounting OfficerSold · $384K · 13,538 sh |
| Mar 26, 2026Form 4 | Fitzgerald MeghanDirectorSold · $1.9M · 70,000 sh |
| Mar 17, 2026Form 4 | Venker EricPresident & Immunovant CEOSold · $5.6M · 200,000 sh · 10b5-1 |
| Mar 16, 2026Form 4 | Epperly Melissa B,DirectorSold · $1.2M · 41,861 sh |
| Feb 23, 2026Form 4 | Torti FrankPresident and Vant ChairSold · $16.2M · 587,390 sh · 10b5-1 |
| Feb 20, 2026Form 4 | Torti FrankPresident and Vant ChairSold · $27.5M · 1,012,610 sh · 10b5-1 |
| Feb 19, 2026Form 4 | Torti FrankPresident and Vant ChairSold · $38.4M · 1,400,000 sh · 10b5-1 |
| Feb 13, 2026Form 4 | QVT Financial LPDirector by DeputizationSold · $10.0M · 375,784 sh |
| Feb 13, 2026Form 4 | Gold Daniel AllenDirectorSold · $10.0M · 375,784 sh |
| Feb 13, 2026Form 4 | MANCHESTER KEITH SDirectorSold · $10.0M · 375,784 sh |
| Feb 13, 2026Form 4 | Venker EricPresident & Immunovant CEOSold · $5.3M · 200,000 sh · 10b5-1 |
| Feb 12, 2026Form 4 | QVT Financial LPDirector by DeputizationSold · $11.4M · 425,000 sh |
| Feb 12, 2026Form 4 | Gold Daniel AllenDirectorSold · $11.4M · 425,000 sh |
| Feb 12, 2026Form 4 | MANCHESTER KEITH SDirectorSold · $11.4M · 425,000 sh |
| Feb 11, 2026Form 4 | QVT Financial LPDirector by DeputizationSold · $11.3M · 425,000 sh |
| Feb 11, 2026Form 4 | Gold Daniel AllenDirectorSold · $11.3M · 425,000 sh |
| Feb 11, 2026Form 4 | MANCHESTER KEITH SDirectorSold · $11.3M · 425,000 sh |
| Feb 9, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorSold · $9.0M · 339,441 sh |
| Jan 12, 2026Form 4 | Venker EricPresident & Immunovant CEOSold · $4.4M · 200,000 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 113 transactions
| Date | Insider |
|---|---|
| Sep 30, 2026Form 4 | Gline MatthewCEO · DirectorTax withholding · $2.8M · 76,171 sh |
| Sep 30, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorTax withholding · $1.7M · 46,879 sh |
| Sep 30, 2026Form 4 | Torti FrankPresident and Vant ChairTax withholding · $1.5M · 40,309 sh |
| Sep 30, 2026Form 4 | Venker EricPresident & Immunovant CEOExercise or conversion · $770K · 200,000 sh · 10b5-1 |
| Sep 30, 2026Form 4 | Venker EricPresident & Immunovant CEOExercise or conversion · Stock Option (Right to Buy) · $0 · 200,000 sh · 10b5-1 |
| Sep 20, 2026Form 4 | Humes JenniferChief Accounting OfficerTax withholding · $154K · 3,880 sh |
| Sep 20, 2026Form 4 | Pulik RichardCFOTax withholding · $85K · 2,129 sh |
| Sep 16, 2026Form 4 | MANCHESTER KEITH SDirectorAward · Stock Option (Right to Buy) · $0 · 10,531 sh |
| Sep 16, 2026Form 4 | MOMTAZEE JAMES CDirectorAward · Stock Option (Right to Buy) · $0 · 10,531 sh |
| Sep 16, 2026Form 4 | Fitzgerald MeghanDirectorAward · Stock Option (Right to Buy) · $0 · 10,531 sh |
| Sep 16, 2026Form 4 | Oren IlanDirectorAward · Stock Option (Right to Buy) · $0 · 10,531 sh |
| Sep 16, 2026Form 4 | Gold Daniel AllenDirectorAward · Stock Option (Right to Buy) · $0 · 10,531 sh |
| Sep 16, 2026Form 4 | Epperly Melissa B,DirectorAward · Stock Option (Right to Buy) · $0 · 10,531 sh |
| Sep 16, 2026Form 4 | MANCHESTER KEITH SDirectorAward · $0 · 5,054 sh |
| Sep 16, 2026Form 4 | MOMTAZEE JAMES CDirectorAward · $0 · 5,054 sh |
| Sep 16, 2026Form 4 | Fitzgerald MeghanDirectorAward · $0 · 5,054 sh |
| Sep 16, 2026Form 4 | Oren IlanDirectorAward · $0 · 5,054 sh |
| Sep 16, 2026Form 4 | Gold Daniel AllenDirectorAward · $0 · 5,054 sh |
| Sep 16, 2026Form 4 | Epperly Melissa B,DirectorAward · $0 · 5,054 sh |
| Sep 10, 2026Form 4 | Gold Daniel AllenDirectorTax withholding · $210K · 5,133 sh |
| Sep 10, 2026Form 4 | MOMTAZEE JAMES CDirectorTax withholding · $119K · 2,905 sh |
| Sep 10, 2026Form 4 | Oren IlanDirectorTax withholding · $97K · 2,378 sh |
| Sep 10, 2026Form 4 | Epperly Melissa B,DirectorTax withholding · $89K · 2,179 sh |
| Sep 10, 2026Form 4 | Fitzgerald MeghanDirectorTax withholding · $71K · 1,743 sh |
| Sep 8, 2026Form 4 | Fitzgerald MeghanDirectorExercise or conversion · $176K · 20,000 sh · 10b5-1 |
| Sep 8, 2026Form 4 | Fitzgerald MeghanDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 20,000 sh · 10b5-1 |
| Aug 28, 2026Form 4 | Venker EricPresident & Immunovant CEOExercise or conversion · $770K · 200,000 sh · 10b5-1 |
| Aug 28, 2026Form 4 | Venker EricPresident & Immunovant CEOExercise or conversion · Stock Option (Right to Buy) · $0 · 200,000 sh · 10b5-1 |
| Aug 21, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $557K · 144,756 sh |
| Aug 21, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 144,756 sh |
| Aug 20, 2026Form 4 | Venker EricPresident & Immunovant CEOTax withholding · $512K · 13,909 sh |
| Aug 20, 2026Form 4 | Pulik RichardCFOTax withholding · $212K · 5,749 sh |
| Aug 20, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $67K · 17,519 sh |
| Aug 20, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 17,519 sh |
| Aug 19, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $666K · 172,899 sh |
| Aug 19, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 172,899 sh |
| Aug 18, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $527K · 136,942 sh |
| Aug 18, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $0 · 136,942 sh |
| Aug 17, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $1.1M · 284,707 sh |
| Aug 17, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $0 · 284,707 sh |
| Aug 14, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $936K · 243,177 sh |
| Aug 14, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $0 · 243,177 sh |
| Jul 27, 2026Form 4 | Venker EricPresident & Immunovant CEOExercise or conversion · $770K · 200,000 sh · 10b5-1 |
| Jul 27, 2026Form 4 | Venker EricPresident & Immunovant CEOExercise or conversion · Stock Option (Right to Buy) · $0 · 200,000 sh · 10b5-1 |
| Jul 17, 2026Form 4 | Oren IlanDirectorAward · $0 · 775 sh |
| Jul 17, 2026Form 4 | Epperly Melissa B,DirectorAward · $0 · 543 sh |
| Jul 17, 2026Form 4 | MOMTAZEE JAMES CDirectorAward · $0 · 405 sh |
| Jun 30, 2026Form 4 | Gline MatthewCEO · DirectorTax withholding · $2.7M · 76,171 sh |
| Jun 30, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorTax withholding · $1.7M · 46,878 sh |
| Jun 30, 2026Form 4 | Torti FrankPresident and Vant ChairTax withholding · $1.4M · 40,310 sh |
| Jun 30, 2026Form 4 | Fitzgerald MeghanDirectorExercise or conversion · $88K · 10,000 sh · 10b5-1 |
| Jun 30, 2026Form 4 | Fitzgerald MeghanDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 10,000 sh · 10b5-1 |
| Jun 29, 2026Form 4 | Epperly Melissa B,DirectorExercise or conversion · $79K · 17,750 sh · 10b5-1 |
| Jun 29, 2026Form 4 | Epperly Melissa B,DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 17,750 sh · 10b5-1 |
| Jun 26, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $1.9M · 500,000 sh |
| Jun 26, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 500,000 sh |
| Jun 25, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $1.9M · 500,000 sh |
| Jun 25, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 500,000 sh |
| Jun 24, 2026Form 4 | Venker EricPresident & Immunovant CEOExercise or conversion · $770K · 200,000 sh · 10b5-1 |
| Jun 24, 2026Form 4 | Venker EricPresident & Immunovant CEOExercise or conversion · Stock Option (Right to Buy) · $0 · 200,000 sh · 10b5-1 |
| Jun 20, 2026Form 4 | Humes JenniferChief Accounting OfficerTax withholding · $113K · 3,582 sh |
| Jun 20, 2026Form 4 | Pulik RichardCFOTax withholding · $67K · 2,129 sh |
| May 22, 2026Form 4 | Venker EricPresident & Immunovant CEOExercise or conversion · $770K · 200,000 sh · 10b5-1 |
| May 22, 2026Form 4 | Venker EricPresident & Immunovant CEOExercise or conversion · Stock Option (Right to Buy) · $0 · 200,000 sh · 10b5-1 |
| May 20, 2026Form 4 | Venker EricPresident & Immunovant CEOTax withholding · $1.1M · 34,483 sh · 10b5-1 |
| May 20, 2026Form 4 | Pulik RichardCFOTax withholding · $615K · 18,962 sh |
| Apr 20, 2026Form 4 | Venker EricPresident & Immunovant CEOExercise or conversion · $770K · 200,000 sh · 10b5-1 |
| Apr 20, 2026Form 4 | Venker EricPresident & Immunovant CEOExercise or conversion · Stock Option (Right to Buy) · $0 · 200,000 sh · 10b5-1 |
| Apr 20, 2026Form 4 | Pulik RichardCFOAward · Stock Option (Right to Buy) · $0 · 84,026 sh |
| Apr 20, 2026Form 4 | Pulik RichardCFOAward · $0 · 60,644 sh |
| Apr 20, 2026Form 4 | Humes JenniferChief Accounting OfficerAward · $0 · 29,173 sh |
| Apr 20, 2026Form 4 | Humes JenniferChief Accounting OfficerAward · Stock Option (Right to Buy) · $0 · 27,157 sh |
| Apr 17, 2026Form 4 | Oren IlanDirectorTax withholding · $2,834 · 95 sh |
| Apr 17, 2026Form 4 | MOMTAZEE JAMES CDirectorTax withholding · $2,804 · 94 sh |
| Apr 17, 2026Form 4 | Oren IlanDirectorAward · $0 · 896 sh |
| Apr 17, 2026Form 4 | Epperly Melissa B,DirectorAward · $0 · 670 sh |
| Apr 17, 2026Form 4 | MOMTAZEE JAMES CDirectorAward · $0 · 469 sh |
| Mar 31, 2026Form 4 | Gline MatthewCEO · DirectorTax withholding · $8.4M · 304,684 sh |
| Mar 31, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorTax withholding · $5.2M · 187,512 sh |
| Mar 31, 2026Form 4 | Torti FrankPresident and Vant ChairTax withholding · $4.4M · 160,035 sh |
| Mar 30, 2026Form 4 | Gline MatthewCEO · DirectorExercise or conversion · $25.0M · 2,178,150 sh |
| Mar 30, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $15.0M · 1,306,889 sh |
| Mar 30, 2026Form 4 | Gline MatthewCEO · DirectorTax withholding · $1.4M · 53,826 sh |
| Mar 30, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorTax withholding · $787K · 29,809 sh |
| Mar 30, 2026Form 4 | Gline MatthewCEO · DirectorExercise or conversion · — · 97,319 sh |
| Mar 30, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · — · 58,391 sh |
| Mar 26, 2026Form 4 | Fitzgerald MeghanDirectorExercise or conversion · $616K · 70,000 sh |
| Mar 26, 2026Form 4 | Fitzgerald MeghanDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 70,000 sh |
| Mar 20, 2026Form 4 | Humes JenniferChief Accounting OfficerTax withholding · $402K · 14,526 sh |
| Mar 20, 2026Form 4 | Pulik RichardCFOTax withholding · $43K · 1,546 sh |
| Mar 17, 2026Form 4 | Venker EricPresident & Immunovant CEOExercise or conversion · $770K · 200,000 sh · 10b5-1 |
| Mar 17, 2026Form 4 | Venker EricPresident & Immunovant CEOExercise or conversion · Stock Option (Right to Buy) · $0 · 200,000 sh · 10b5-1 |
| Feb 23, 2026Form 4 | Torti FrankPresident and Vant ChairExercise or conversion · $2.3M · 587,390 sh · 10b5-1 |
| Feb 23, 2026Form 4 | Torti FrankPresident and Vant ChairExercise or conversion · Stock Option (Right to Buy) · $0 · 587,390 sh · 10b5-1 |
| Feb 20, 2026Form 4 | Torti FrankPresident and Vant ChairExercise or conversion · $3.9M · 1,012,610 sh · 10b5-1 |
| Feb 20, 2026Form 4 | Venker EricPresident & Immunovant CEOTax withholding · $191K · 7,051 sh |
| Feb 20, 2026Form 4 | Pulik RichardCFOTax withholding · $27K · 1,000 sh |
| Feb 20, 2026Form 4 | Torti FrankPresident and Vant ChairExercise or conversion · Stock Option (Right to Buy) · $0 · 1,012,610 sh · 10b5-1 |
| Feb 19, 2026Form 4 | Torti FrankPresident and Vant ChairExercise or conversion · $5.4M · 1,400,000 sh · 10b5-1 |
| Feb 19, 2026Form 4 | Torti FrankPresident and Vant ChairExercise or conversion · Stock Option (Right to Buy) · $0 · 1,400,000 sh · 10b5-1 |
| Feb 13, 2026Form 4 | Venker EricPresident & Immunovant CEOExercise or conversion · $770K · 200,000 sh · 10b5-1 |
| Feb 13, 2026Form 4 | Venker EricPresident & Immunovant CEOExercise or conversion · Stock Option (Right to Buy) · $0 · 200,000 sh · 10b5-1 |
| Feb 9, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · $8.3M · 651,558 sh |
| Feb 9, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorOther · $8.3M · 312,117 sh |
| Feb 9, 2026Form 4 | Sukhatme MayukhPresident & CIO · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 651,558 sh |
| Jan 20, 2026Form 4 | Oren IlanDirectorTax withholding · $2,850 · 124 sh |
| Jan 20, 2026Form 4 | MOMTAZEE JAMES CDirectorTax withholding · $2,804 · 122 sh |
| Jan 20, 2026Form 4 | Epperly Melissa B,DirectorTax withholding · $1,241 · 54 sh |
| Jan 20, 2026Form 4 | Oren IlanDirectorAward · $0 · 1,164 sh |
| Jan 20, 2026Form 4 | Epperly Melissa B,DirectorAward · $0 · 815 sh |
| Jan 20, 2026Form 4 | MOMTAZEE JAMES CDirectorAward · $0 · 609 sh |
| Jan 12, 2026Form 4 | Venker EricPresident & Immunovant CEOExercise or conversion · $770K · 200,000 sh · 10b5-1 |
| Jan 12, 2026Form 4 | Venker EricPresident & Immunovant CEOExercise or conversion · Stock Option (Right to Buy) · $0 · 200,000 sh · 10b5-1 |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K is described by its items. A form opens the document on EDGAR, or the filing’s index where it furnishes exhibits (an earnings release is the 8-K’s Exhibit 99.1).
2026 · 17 filings
| Filed | What it is |
|---|---|
| Sep 18, 20268-K | Shareholder vote results |
| Sep 8, 20268-K | Regulation FD disclosure |
| Aug 28, 20268-K | Other events |
| Aug 27, 20268-K | Regulation FD disclosure |
| Aug 6, 202610-Q | Quarterly report, Q1 2026 — revenue $1.4M (−34% y/y), net income −$189.8M, EPS −$0.26 |
| Aug 6, 20268-K | Earnings release — EPS −$0.45 vs −$0.45 est. (+0.0%); revenue $1.4M (−34% y/y) 1.5% |
| Jul 29, 2026ARS | Annual report to shareholders |
| Jul 29, 2026DEFA14A | Additional proxy materials |
| Jul 29, 2026DEF 14A | Proxy statement |
| May 20, 202610-K | Annual report, FY2025 — revenue $8.3M (−72% y/y), net income −$299.8M, EPS −$0.54 |
| May 20, 20268-K | Earnings release — EPS −$0.46 vs −$0.38 est. (−21.1%); revenue $2.5M (−67% y/y) 14.9% |
| Apr 2, 20268-K | Results of operations; Regulation FD disclosure |
| Mar 23, 20268-K/A | Material definitive agreement |
| Mar 3, 20268-K | Material definitive agreement; Regulation FD disclosure; Other events |
| Mar 3, 20268-K | Regulation FD disclosure |
| Feb 6, 202610-Q | Quarterly report, Q3 2025 — revenue $2.0M (−78% y/y), net income −$265.9M, EPS −$0.38 |
| Feb 6, 20268-K | Earnings release — EPS −$0.36 vs −$0.39 est. (+7.7%); revenue $2.0M (−78% y/y) 22.1% |
2025 · 20 filings
| Filed | What it is |
|---|---|
| Dec 11, 20258-K | Regulation FD disclosure |
| Nov 10, 202510-Q | Quarterly report, Q2 2025 — revenue $1.6M (−65% y/y), net income −$113.5M, EPS −$0.17 |
| Nov 10, 20258-K | Earnings release — EPS −$0.40 vs −$0.34 est. (−17.6%); revenue $1.6M (−65% y/y) 2.7% |
| Sep 17, 20258-K | Regulation FD disclosure; Other events |
| Sep 11, 20258-K | Shareholder vote results |
| Sep 3, 20258-K | Regulation FD disclosure; Other events |
| Aug 11, 202510-Q | Quarterly report, Q1 2025 — revenue $2.2M (−73% y/y), net income −$223.4M, EPS −$0.33 |
| Aug 11, 20258-K | Results of operations |
| Jul 29, 2025ARS | Annual report to shareholders |
| Jul 29, 2025DEF 14A | Proxy statement |
| Jul 29, 2025DEFA14A | Additional proxy materials |
| Jun 25, 20258-K | Other events |
| May 29, 202510-K | Annual report, FY2024 — revenue $29.1M (−11% y/y), net income −$172.0M, EPS −$0.24 |
| May 29, 20258-K | Results of operations |
| Apr 21, 20258-K | Regulation FD disclosure |
| Mar 20, 20258-K | Directors or officers; compensation |
| Mar 19, 20258-K | Regulation FD disclosure; Other events |
| Feb 21, 20258-K | Directors or officers; compensation |
| Feb 10, 202510-Q | Quarterly report, Q3 2024 — revenue $9.0M (−42% y/y), net income $169.4M, EPS $0.23 |
| Feb 10, 20258-K | Results of operations |
2024 · 20 filings
| Filed | What it is |
|---|---|
| Dec 3, 20248-K | Regulation FD disclosure |
| Nov 12, 202410-Q | Quarterly report, Q2 2024 — revenue $4.5M (+23% y/y), net income −$230.2M, EPS −$0.31 |
| Nov 12, 20248-K | Results of operations |
| Oct 28, 20248-K | Termination of a material agreement; Regulation FD disclosure |
| Sep 23, 20248-K | Material definitive agreement |
| Sep 18, 20248-K | Regulation FD disclosure |
| Sep 16, 20248-K | Shareholder vote results |
| Sep 10, 20248-K | Regulation FD disclosure |
| Sep 9, 20248-K | Regulation FD disclosure |
| Aug 9, 202410-Q | Quarterly report, Q1 2024 — revenue $8.0M (−63% y/y), net income $95.3M, EPS $0.12 |
| Aug 8, 20248-K | Results of operations |
| Jul 26, 2024ARS | Annual report to shareholders |
| Jul 26, 2024DEFA14A | Additional proxy materials |
| Jul 26, 2024DEF 14A | Proxy statement |
| May 30, 202410-K | Annual report, FY2023 — revenue $32.7M (+4% y/y), net income $4.35B, EPS $5.23 |
| May 30, 20248-K | Material definitive agreement |
| May 30, 20248-K | Results of operations |
| Apr 2, 20248-K | Other events |
| Feb 13, 202410-Q | Quarterly report, Q3 2023 — revenue $15.6M (−9% y/y), net income $5.10B, EPS $6.03 |
| Feb 13, 20248-K | Results of operations |
2023 · 34 filings — 25 × 8-K, 3 × 10-Q, 2 × 8-K/A and 4 other forms
| Filed | What it is |
|---|---|
| Nov 13, 202310-Q | Quarterly report, Q2 2023 — revenue $3.6M (−71% y/y), net income −$304.3M, EPS −$0.40 |
| Aug 14, 202310-Q | Quarterly report, Q1 2023 — revenue $21.6M (+401% y/y), net income −$291.8M, EPS −$0.38 |
| Aug 7, 2023ARS | Annual report to shareholders |
| Jul 31, 2023DEFA14A | Additional proxy materials |
| Jul 31, 2023DEF 14A | Proxy statement |
| Jun 28, 202310-K | Annual report, FY2022 — revenue $31.5M (−43% y/y), net income −$1.01B, EPS −$1.42 |
| Feb 13, 202310-Q | Quarterly report, Q3 2022 — revenue $17.1M (−30% y/y), net income −$352.0M, EPS −$0.49 |
27 current reports (8-K) not listed; the year is on EDGAR.
2022 · 19 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 14, 202210-Q | Quarterly report, Q2 2022 — revenue $12.5M (−10% y/y), net income −$291.6M, EPS −$0.42 |
| Aug 15, 202210-Q | Quarterly report, Q1 2022 — revenue $4.3M (−44% y/y), net income −$331.8M, EPS −$0.48 |
| Jul 26, 2022DEFA14A | Additional proxy materials |
| Jul 26, 2022DEF 14A | Proxy statement |
| Jun 28, 202210-K | Annual report, FY2021 — revenue $55.3M (+132% y/y), net income −$845.3M, EPS −$1.26 |
| Feb 14, 202210-Q | Quarterly report, Q3 2021 — revenue $24.3M, net income −$284.5M, EPS −$0.41 |
13 current reports (8-K) not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 112 filings — 71 × 4, 30 × 144, 9 × SCHEDULE 13G/A and 2 other forms
| Filed | What it is |
|---|---|
| Oct 2, 20264 | Insider transaction (Form 4) |
| Oct 2, 20264 | Insider transaction (Form 4) |
| Oct 2, 20264 | Insider transaction (Form 4) |
| Oct 2, 20264 | Insider transaction (Form 4) |
| Sep 30, 2026144 | Notice of proposed sale (Form 144) |
| Sep 22, 20264 | Insider transaction (Form 4) |
| Sep 22, 20264 | Insider transaction (Form 4) |
| Sep 18, 20264 | Insider transaction (Form 4) |
| Sep 18, 20264 | Insider transaction (Form 4) |
| Sep 18, 20264 | Insider transaction (Form 4) |
| Sep 18, 20264 | Insider transaction (Form 4) |
| Sep 18, 20264 | Insider transaction (Form 4) |
| Sep 18, 20264 | Insider transaction (Form 4) |
| Sep 17, 20264 | Insider transaction (Form 4) |
| Sep 17, 20264 | Insider transaction (Form 4) |
| Sep 15, 2026144 | Notice of proposed sale (Form 144) |
| Sep 15, 2026144 | Notice of proposed sale (Form 144) |
| Sep 14, 20264 | Insider transaction (Form 4) |
| Sep 14, 20264 | Insider transaction (Form 4) |
| Sep 14, 20264 | Insider transaction (Form 4) |
| Sep 14, 20264 | Insider transaction (Form 4) |
| Sep 14, 20264 | Insider transaction (Form 4) |
| Sep 10, 20264 | Insider transaction (Form 4) |
| Sep 8, 2026144 | Notice of proposed sale (Form 144) |
| Sep 1, 20264 | Insider transaction (Form 4) |
The newest 25 of 112 shown; the full year is on EDGAR.
2025 · 151 filings — 88 × 4, 42 × 144, 10 × SCHEDULE 13G/A and 5 other forms
| Filed | What it is |
|---|---|
| Dec 31, 20254 | Insider transaction (Form 4) |
| Dec 31, 2025144 | Notice of proposed sale (Form 144) |
| Dec 29, 20254 | Insider transaction (Form 4) |
| Dec 29, 20254 | Insider transaction (Form 4) |
| Dec 29, 20254 | Insider transaction (Form 4) |
| Dec 29, 2025144 | Notice of proposed sale (Form 144) |
| Dec 29, 2025144 | Notice of proposed sale (Form 144) |
| Dec 29, 2025144 | Notice of proposed sale (Form 144) |
| Dec 23, 20254 | Insider transaction (Form 4) |
| Dec 23, 2025144 | Notice of proposed sale (Form 144) |
| Dec 23, 2025144 | Notice of proposed sale (Form 144) |
| Dec 23, 2025144 | Notice of proposed sale (Form 144) |
| Dec 19, 20254 | Insider transaction (Form 4) |
| Dec 18, 20254 | Insider transaction (Form 4) |
| Dec 18, 20254 | Insider transaction (Form 4) |
| Dec 18, 20254 | Insider transaction (Form 4) |
| Dec 17, 20254 | Insider transaction (Form 4) |
| Dec 17, 2025144 | Notice of proposed sale (Form 144) |
| Dec 15, 20254 | Insider transaction (Form 4) |
| Dec 15, 2025144/A | Notice of proposed sale (Form 144), amended |
| Dec 15, 2025144 | Notice of proposed sale (Form 144) |
| Dec 12, 2025SCHEDULE 13D/A | Other filings |
| Dec 12, 20254 | Insider transaction (Form 4) |
| Dec 11, 20254 | Insider transaction (Form 4) |
| Dec 9, 2025144 | Notice of proposed sale (Form 144) |
The newest 25 of 151 shown; the full year is on EDGAR.
2024 · 135 filings — 96 × 4, 22 × 144, 12 × SC 13G/A and 3 other forms
| Filed | What it is |
|---|---|
| Dec 31, 20244 | Insider transaction (Form 4) |
| Dec 31, 20244 | Insider transaction (Form 4) |
| Dec 27, 2024144 | Notice of proposed sale (Form 144) |
| Dec 26, 20244 | Insider transaction (Form 4) |
| Dec 26, 20244 | Insider transaction (Form 4) |
| Dec 26, 20244 | Insider transaction (Form 4) |
| Dec 26, 20244 | Insider transaction (Form 4) |
| Dec 26, 20244 | Insider transaction (Form 4) |
| Dec 26, 2024144 | Notice of proposed sale (Form 144) |
| Dec 26, 2024144 | Notice of proposed sale (Form 144) |
| Dec 23, 2024144 | Notice of proposed sale (Form 144) |
| Dec 20, 20244 | Insider transaction (Form 4) |
| Dec 20, 2024144 | Notice of proposed sale (Form 144) |
| Dec 18, 2024144 | Notice of proposed sale (Form 144) |
| Dec 5, 20244 | Insider transaction (Form 4) |
| Dec 2, 20244 | Insider transaction (Form 4) |
| Nov 22, 20244 | Insider transaction (Form 4) |
| Nov 22, 20244 | Insider transaction (Form 4) |
| Nov 22, 20244 | Insider transaction (Form 4) |
| Nov 20, 2024144 | Notice of proposed sale (Form 144) |
| Nov 14, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Nov 12, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Nov 12, 2024SC 13G | Passive holder above 5% (Schedule 13G) |
| Nov 8, 2024SC 13G | Passive holder above 5% (Schedule 13G) |
| Nov 4, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
The newest 25 of 135 shown; the full year is on EDGAR.
2023 · 223 filings — 119 × 4, 84 × 144, 6 × SC 13G/A and 10 other forms
Counted, not listed; the year is on EDGAR.
2022 · 109 filings — 60 × 4, 17 × 424B3, 7 × EFFECT and 11 other forms
Counted, not listed; the year is on EDGAR.
2021 · 64 filings — 20 × 3, 9 × 425, 6 × CORRESP and 13 other forms
Counted, not listed; the year is on EDGAR.
2020 · 10 filings — 5 × 4, 5 × SC 13D/A
Counted, not listed; the year is on EDGAR.
2019 · 35 filings — 17 × 4, 14 × SC 13D/A, 2 × SC 13D and 2 other forms
Counted, not listed; the year is on EDGAR.
2018 · 14 filings — 6 × SC 13D/A, 5 × 4, 2 × SC 13D and 1 other form
Counted, not listed; the year is on EDGAR.
2017 · 4 filings — 2 × SC 13D/A, 1 × 4, 1 × SC 13G
Counted, not listed; the year is on EDGAR.
2016 · 3 filings — 1 × 3, 1 × SC 13D/A, 1 × SC 13G
Counted, not listed; the year is on EDGAR.
2015 · 4 filings — 2 × 3, 1 × SC 13D, 1 × SC 13D/A
Counted, not listed; the year is on EDGAR.
About this data
Roivant Sciences Ltd. (ROIV) has 980 filings on EDGAR going back to 2015: 5 annual reports, 16 quarterly reports and 81 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on May 20, 2026 for the fiscal year ended Mar 31, 2026. The most recent 8-K, on Sep 18, 2026, covered shareholder vote results. Over the last 13 months insiders sold $484.3M in 48 sales and bought nothing on the open market; 113 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Roivant Sciences Ltd., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read ROIV's latest 10-K?
- ROIV's latest annual report, a 10-K, was filed on May 20, 2026 for the fiscal year ended Mar 31, 2026. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did ROIV last file an 8-K?
- On Sep 18, 2026: shareholder vote results. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Aug 6, 2026.
- Are ROIV insiders buying or selling?
- Over the last 13 months insiders sold $484.3M in 48 sales and bought nothing on the open market; 113 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Venker Eric (President & Immunovant CEO) sold 200,000 shares on Sep 30, 2026 for $7.3M, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has ROIV made?
- 980 filings are on EDGAR under the registrant records that have been Roivant Sciences Ltd., going back to 2015; 679 of them are insider ownership forms (Forms 3, 4, 5 and 144).